



Cat No: **OVC1501 - Ovary cancer tissue array**

Lot#	Cores	Size	Cut	Format	QA/QC	Pantomics, Inc.	
OVC150101	150	1.1mm	4um	10X15	H&E, IHC anti-Cytokeratin		

**Recommended applications:** For Research use only. RNA or protein ovary cancer/non-tumor tissue profiling using IHC or ISH; Antibody characterization.

**Description:** Ovarian cancer tissue array, 150 cores including 75 cases of uninvolved and neoplastic tissues of the ovary in duplicates. All the tissues were from surgical resection. They were fixed in 10% neutral buffered formalin for 24 hours and processed using identical SOPs. Sections were picked onto Superfrost Plus or APES coated Superfrost slides. They all have a guaranteed six months' shelf-life at 4C from the date of shipment. Each slide has >95% tissue core retention.

Array position	Age	Sex	Anatomic site	Histology	Grade	Stage (TNM)
A1,B1	40	F	Ovary	Normal		
A2,B2	40	F	Ovary	Normal		
A3,B3	19	F	Ovary	Mucinous cystadenoma		
A4,B4	35	F	Ovary	Thecoma		
A5,B5	42	F	Ovary	Boderline serous cystadenoma		
A6,B6	53	F	Ovary	Serous cystadenocarcinoma	III	T1N0M0
A7,B7	56	F	Ovary	Serous cystadenocarcinoma	II~III	T2N1M0
A8,B8	40	F	Ovary	Metastatic cancer from colon		
A9,B9	58	F	Ovary	Serous cystadenocarcinoma		T1N0M0
A10,B10	50	F	Ovary	Endometrioid adenocarcinoma	II~III	T2N1M0
A11,B11	65	F	Ovary	Serous cystadenocarcinoma		T1N0M0
A12,B12	42	F	Ovary	Undifferentiated carcinoma		T2N0M0
A13,B13	9	F	Ovary	Endometrioid adenocarcinoma	II	T1N0M0
A14,B14	51	F	Ovary	Serous cystadenocarcinoma		T2N0M0
A15,B15	20	F	Ovary	Serous cystadenocarcinoma	II	T2N0M0
C1,D1	47	F	Ovary	Serous cystadenocarcinoma	III	T1N0M0
C2,D2	53	F	Ovary	Serous cystadenocarcinoma	III	T1N0M0
C3,D3	48	F	Ovary	Undifferentiated carcinoma		T2N0M0
C4,D4	44	F	Ovary	Endometrioid adenocarcinoma	II	T1N0M0
C5,D5	51	F	Ovary	Serous cystadenocarcinoma	III	T3N1M0
C6,D6	65	F	Ovary	Endometrioid adenocarcinoma	III	T2N0M0
C7,D7	43	F	Ovary	Serous cystadenocarcinoma	III	T1N0M0
C8,D8	45	F	Ovary	Serous cystadenocarcinoma	III	T1N0M0
C9,D9	82	F	Ovary	Endometrioid adenocarcinoma	I	T1N0M0
C10,D10	47	F	Ovary	Mucinous cystadenocacinoma	I	T1N0M0
C11,D11	43	F	Ovary	Mucinous cystadenocacinoma	III	T2N0M0
C12,D12	63	F	Ovary	Endometrioid adenocarcinoma	III	T1N0M0
C13,D13	54	F	Ovary	Undifferentiated adenocarcinoma		T2N0M0
C14,D14	56	F	Ovary	Serous cystadenocarcinoma	I	T1N0M0
C15,D15	34	F	Ovary	Serous cystadenocarcinoma	I	T2N0M0
E1,F1	24	F	Ovary	Mucinous cystadenocacinoma	I	T1N0M0
E2,F2	58	F	Ovary	Endometrioid adenocarcinoma	III	T2N0M0
E3,F3	25	F	Ovary	Endometrioid adenocarcinoma	II	T2N0M0
E4,F4	51	F	Ovary	Endometrioid adenocarcinoma	I	T1N0M0
E5,F5	25	F	Ovary	Mucinous cystadenocacinoma	I	T1N0M0
E6,F6	50	F	Ovary	Endometrioid adenocarcinoma	I	T2N0M0



## Advancing Biomedical Science Through Tissue Arrays

E7,F7	40	F	Ovary	Endometrioid adenocarcinoma		T1NOMO
E8,F8	34	F	Ovary	Endometrioid adenocarcinoma		T1NOMO
E9,F9	33	F	Ovary	Serous cystadenocarcinoma	I	T1NOMO
E10,F10	52	F	Ovary	Endometrioid adenocarcinoma	III	T2NOMO
E11,F11	42	F	Ovary	Endometrioid adenocarcinoma	I	T1NOMO
E12,F12	68	F	Ovary	Endometrioid adenocarcinoma	III	T1NOMO
E13,F13	17	F	Ovary	Endometrioid adenocarcinoma	I	T1NOMO
E14,F14	38	F	Ovary	Mucinous cystadenocacinoma	I	T1NOMO
E15,F15	48	F	Ovary	Mucinous cystadenocacinoma	III	T1NOMO
G1,H1	18	F	Ovary	Serous cystadenocarcinoma	II	T1NOMO
G2,H2	36	F	Ovary	Sarcoma		T1NOMO
G3,H3	42	F	Ovary	Serous cystadenocarcinoma	II ~ III	T1NOMO
G4,H4	42	F	Ovary	Serous cystadenocarcinoma	II ~ III	T1NOMO
G5,H5	23	F	Ovary	Endodermal sinus tumor		
G6,H6	45	F	Ovary	Serous cystadenocarcinoma	III	T2NOMO
G7,H7	18	F	Ovary	Mucinous cystadenocacinoma	I	T2NOMO
G8,H8	48	F	Ovary	Serous cystadenocarcinoma	II	T2NOMO
G9,H9	49	F	Ovary	Endometrioid adenocarcinoma	III	T2NOMO
G10,H10	51	F	Ovary	Endometrioid adenocarcinoma	III	T2NOMO
G11,H11	48	F	Ovary	Mucinous cystadenocacinoma	I	T2NOMO
G12,H12	43	F	Ovary	Granulosa cell tumor		T1NOMO
G13,H13	51	F	Ovary	Serous cystadenocarcinoma	III	T2NOMO
G14,H14	71	F	Ovary	Endometrioid adenocarcinoma	III	T3NOMO
G15,H15	58	F	Ovary	Endometrioid adenocarcinoma	III	T2NOMO
I1,J1	17	F	Ovary	Dysgerminoma		
I2,J2	50	F	Ovary	Endometrioid adenocarcinoma	III	T2NOMO
I3,J3	44	F	Ovary	Serous cystadenocarcinoma	III	T2NOMO
I4,J4	54	F	Ovary	Serous cystadenocarcinoma	III	T2NOMO
I5,J5	39	F	Ovary	Mucinous cystadenocacinoma	I	T2NOMO
I6,J6	39	F	Ovary	Endometrioid adenocarcinoma	III	T2NOMO
I7,J7	53	F	Ovary	Mucinous cystadenocacinoma	II	T2NOMO
I8,J8	43	F	Ovary	Endometrioid adenocarcinoma	I	T2NOMO
I9,J9	74	F	Ovary	Serous cystadenocarcinoma	III	T2NOMO
I10,J10	52	F	Ovary	Endometrioid adenocarcinoma	II	T1NOMO
I11,J11	56	F	Ovary	Serous cystadenocarcinoma	III	T2NOMO
I12,J12	54	F	Ovary	Endometrioid adenocarcinoma	III	T1NOMO
I13,J13	54	F	Ovary	Serous cystadenocarcinoma	III	T2NOMO
I14,J14	48	F	Ovary	Mucinous cystadenocacinoma	I ~ II	T1NOMO
I15,J15	62	F	Ovary	Mucinous cystadenocacinoma	II	T2NOMO

**Notes:** Bake at 60C for 30 minutes before use. If antigen retrieving is needed, it is always a good idea to start with a protocol with weak to mild strength.

**Certified by:** Fancai Li, M.D.



## TNM Classification: Ovary carcinoma

### T- Primary tumor

TX - Primary tumor cannot be assessed

TO - No evidence of primary tumor

T1 - Tumor limited to the ovaries

T1a - Tumor limited to one ovary; capsule intact, no tumor invasion on ovarian surface; no malignant cells in ascites or peritoneal washings

T1b - Tumor limited to both ovaries; capsule intact, no tumor invasion on ovarian surface; no malignant cells in ascites or peritoneal washings

T1c - Tumor limited to one or both ovaries with any or the following features; capsule ruptured, tumor on ovarian surface, malignant cells in ascites or peritoneal washing

T2 - Tumor involves one or both ovaries with pelvic extension

T2a - Extension and/or implants on uterus and/or tube(s); no malignant cells in ascites or peritoneal washings

T2b - Extension to other pelvic tissue; no malignant cells in ascites or peritoneal washings

T2c - Pelvic extension (T2a or T2b) with malignant cells in ascites or peritoneal washings

T3 and/or N1 - Tumor involves both ovaries with microscopically confirmed peritoneal metastasis outside the pelvis and/or regional lymph node metastasis

T3a - Microscopic peritoneal metastasis beyond pelvis

T3b - Macroscopic peritoneal metastasis beyond pelvis 2 cm or less in greatest dimension

T3c and/or N1 - Peritoneal metastasis beyond pelvis more than 2 cm in greatest dimension and/or regional lymph node metastasis

### N - Regional lymph nodes

NX - Regional lymph nodes cannot be assessed

NO - No regional lymph node metastasis

N1 - Regional lymph node metastasis

### M - Distant metastasis

MX - Distant metastasis cannot be assessed

MO - No distant metastasis

M1 - Distant metastasis (exclude peritoneal metastasis)

### Comparison between TNM vs. FIGO

TNM category	FIGO stage	TNM category	FIGO stage
T1	I	T3 and/or N1	III
T1a	IA	T3a	IIIA
T1b	IB	T3b	IIIB
T1c	IC	T3c and/or N1	IIIC
T2	II	M1	IV
T2a	IIA		
T2b	IIB		
T2c	IIC		

TNM classification of malignant tumours, Fifth Edition (1997)